|
Patient Characteristics (Intent-To-Treat Population) |
||||||
| Parameter |
Engerix®-B |
HBsAg alone |
HBsAg + 3 μg IMP321 |
HBsAg + 10 μg IMP321 |
HBsAg + 30 μg IMP321 |
HBsAg + 100 μg IMP321 |
|
|
||||||
| Number enrolled |
8 |
8 |
9 |
9 |
8 |
8 |
| Number completed |
8 |
8 |
8 |
8 |
8 |
8 |
| Age (years)a Mean ± SD |
32.1 ± 11.2 |
41.0 ± 11.4 |
31.4 ± 8.0 |
29.0 ± 9.2* |
37.3 ± 9.7 |
35.9 ± 7.4 |
| Genderb |
||||||
| Male |
7 |
7 |
9 |
9 |
8 |
8 |
| Female |
1 |
1 |
0 |
0 |
0 |
0 |
| Raceb |
||||||
| Caucasian |
7 |
6 |
6 |
5 |
6 |
7 |
| Black |
1 |
1 |
1 |
2 |
2 |
1 |
| Asian |
0 |
0 |
1 |
1 |
0 |
0 |
| Other |
0 |
1 |
1 |
1 |
0 |
0 |
|
a Student's t-test. * p < 0.05 compared to HBsAg alone control group. b Chi-square. P >0.05 compared to HBsAg alone control group. | ||||||
Brignone et al. Journal of Immune Based Therapies and Vaccines 2007 5:5 doi:10.1186/1476-8518-5-5 |
||||||